Cohen & Steers Inc (CNS) Stock Price & How to Invest

Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT).

The investment picture centers on assets under management, which reached about $93.1 billion in early 2026 and drives nearly all revenue. Because CNS is concentrated in real estate and rate-sensitive income strategies, its AUM and flows are heavily influenced by interest rates: the Federal Reserve's late-2024 pivot to rate cuts coincided with a return to net inflows across several quarters. The business runs at high operating margins and pays a meaningful dividend, but it carries the classic asset-manager sensitivity to market drawdowns and to any rotation away from its specialty categories.

CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. Its concentration in real estate and rate-sensitive income means a reversal to higher-for-longer rates, or a rotation away from REITs and preferreds, could trigger outflows and market depreciation at the same time. The active-management fee model faces secular pressure from low-cost passive and index products, and net flows can turn negative in stressed markets. Newer private and non-traded initiatives add execution and liquidity risk, and results can be lumpy quarter to quarter.

3 analysts publish price targets on CNS, averaging $73.67 against a $82.27 price as of August 2026, or -10.5%. The published targets run from $60.00 to $84.00, a moderate spread, and the ratings split 1 buy, 1 hold, 1 sell. Over the last six months there has been 1 raise and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CNS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Cohen & Steers Inc. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Rate-cut tailwind for real assets. Listed real estate and preferred securities are rate-sensitive, and the shift toward Fed rate cuts has coincided with renewed net inflows for CNS. The most optimistic published target, $84.00, assumes this works close to its best case.

The case against. CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. The most pessimistic target, $60.00, is roughly what CNS is worth if this bites instead.

Read the full bull and bear case on CNS, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Cohen & Steers Inc's investor relations page or your broker.

• Assets under management: ~$93.1B
• Revenue (Q1 2026): ~$145.6M
• Q1 2026 net inflows: ~$497M
• Diluted EPS (Q1 2026): ~$0.82
• Market cap: ~$3.4B
• Dividend yield: ~3.7%

As of April 2026, CNS traded around a mid-20s price-to-earnings multiple with a dividend yield near 3.7%, reflecting its status as a profitable, dividend-paying specialty manager. Q1 2026 revenue of about $145.6 million grew roughly 8% year over year, and operating margin improved to about 34%. Because fees scale with AUM, valuation and earnings hinge on the direction of markets and flows into real-asset strategies.

Other names that sit close to CNS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CNS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CNS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CNS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CNS is a focused, high-margin real-assets manager whose fortunes track AUM, flows, and the interest-rate backdrop for REITs and preferreds.

Whether CNS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CNS a buy or a sell?, and where the stock could go from here in the CNS stock forecast.

For income investors, whether CNS pays a dividend and how the payout looks is covered in does CNS pay a dividend? And to weigh CNS against a peer, read the full side-by-side comparisons: CNS vs BN and CNS vs IVZ.